NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ — DarioHealth Corp. (“DarioHealth” or “Dario”) (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled “Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device.” The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage™ platform to facilitate digital health interventions based on the data analysis.
“Dario’s business and product strategy is guided by evidence that shows that increased user engagement and direct empowerment of individuals to manage their personal health leads to better medical outcomes,” said Erez Raphael, DarioHealth’s chief executive officer. “As a result, our product innovation has continually focused on enhancing Dario’s user experience and developing new ways to integrate intelligent, medical device technology with the smartphone to make health and chronic condition management easy, affordable and convenient.”
DarioHealth’s digital therapeutics solutions are unique in that they capture and analyze members’ real-time, clinical data using a member’s smartphone and allow for full access and connectivity to that data at any time throughout the day, along with personalized daily and weekly health data reports. This provides Dario members a fully personalized, integrated and exceptionally convenient platform to manage their health throughout the day, and facilitates a heightened user experience, increased user engagement and improved clinical health outcomes.
As the future of healthcare becomes increasingly digitized and focused on empowering individuals to take control of their personal health, DarioHealth believes smartphones will serve as the primary conduit for health interventions and chronic condition management.
As a pioneer in the digital therapeutics industry, DarioHealth supports the evolution of iOS and Android mobile devices and continually seeks opportunities to use smartphones as the primary health management device, integrated with connected medical devices, rather than requiring users to purchase and use a secondary device that has to synchronize information with a smartphone, which is less convenient, effective and efficient.
DarioHealth plans to begin development of new paired smartphone medical devices in the coming year, which will further advance the company’s objective of providing highly effective, inexpensive and convenient digital therapeutic health solutions that empower individuals to best manage their chronic health conditions and improve their overall health.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company discusses its belief that smartphones will serve as the primary conduit for health interventions and chronic condition management and its plans to begin development of new paired smartphone medical devices in the coming year, which will further advance the company’s objective of providing highly effective, inexpensive and convenient digital therapeutic health solutions that empower individuals to best manage their chronic health conditions and improve their overall health, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Original Article: (https://www.prnewswire.com/news-releases/dariohealth-awarded-us-patent-for-optical-transmission-of-data-between-a-sensor-and-smart-device-300920682.html)